Following the widespread clinical use of next-generation ARPIs, the proportion of AR-null prostate cancer, including neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC), has subsequently risen as a means of drug resistance [8]. The gene discussed is AR; the disease is Familial prostate cancer.